Eisai R&d Management Co., Ltd.

Takashi Satoh

Hans J Hansen

John JianShi Wang

Lynn D Hawkins

Ming-Hong Hao

Atsushi Endo

Dominic J Reynolds

Sally T Ishizaka

Shawn Schiller

Roch Boivin

Eric Carlson

Sudeep Prajapati

Sridhar Narayan

Matthew Mackey

Anand Selvaraj

Mark Spyvee

Jonathan Eric Carlson

Arani Chanda

Kristen Sanders

George Moniz

Kenshi Yoshida

Dominic Reynolds

Sundeep Prajapati

A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.

Crystalline FGFR4 inhibitor compound and uses thereof

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Tetrahydropyrazolopyrimidine compounds

Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.

Pyrimidine FGFR4 inhibitors

The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.

Pharmaceutical composition

Growing community of inventors

Andover, MA, United States of America

Takashi Satoh